Nov 9, 2026 · 7 min
AI spending fears and drug setbacks hit market darlings
Nvidia Drops, DraftKings Slips, Ionis Pharma Falls After FY Guidance
The episode shows how governance questions, profit pressure, regulatory uncertainty, and failed drug development can quickly reshape investor expectations.
- 1Nvidia faces leadership concerns and broader doubts about technology-sector strength and AI spending before earnings.
- 2DraftKings lowered profit guidance while investing in prediction markets, drawing analyst downgrades and renewed regulatory scrutiny.
- 3Ionis cut Tringolza sales expectations as Novartis ended pelacarsen development after an unsuccessful trial.
Don't miss
Ionis’s setbacks compound when weaker Tringolza sales expectations are followed by Novartis ending pelacarsen development after an unsuccessful trial.
The brief
Stock Movers host Tim Stenovec and Bloomberg earnings reporter Chloe Melley examine sharp declines at Nvidia, DraftKings, and Ionis Pharmaceuticals, separating company-specific problems from broader market pressure.
Nvidia is under pressure from controversy involving CEO Jensen Huang, technology-sector weakness, and investor concern about AI spending ahead of earnings.
DraftKings faces weaker profit guidance as it invests heavily in prediction markets, while analyst downgrades and regulatory uncertainty add to the pressure.
Ionis lowered expectations after a weaker-than-expected Tringolza launch, then absorbed another setback when partner Novartis abandoned pelacarsen development after an unsuccessful trial.
Together, the moves show how quickly markets punish uncertainty around leadership, spending, regulation, commercial launches, and clinical results.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.